Income statement
CAD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -115K | -136K | -288K | -192K | -159K |
| EBITDA | 0 | 0 | 0 | 0 | 0 |
| Net Income | -115K | -91K | 1M | -192K | -44K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0021
+0.00% today
1Y Change
-4.55%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Verisante Technology Inc. (VRSEF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 4.5% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +125.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +125.9%, free cash flow 0.0% with operating margin 0.0% and ROIC 1169.8%. Valuation is more restrained than many high-expectation growth names at P/E 2.1. Stock Foundry combines VRSEF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRSEF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VRSEF Max Drawdown
-98.46%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VRSEF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$44.0K
+77.1% YoY
Free Cash Flow
-$45.5K
-12.4% YoY
Revenue Growth
+0.0%
EPS Growth
+125.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -115K | -136K | -288K | -192K | -159K |
| EBITDA | 0 | 0 | 0 | 0 | 0 |
| Net Income | -115K | -91K | 1M | -192K | -44K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8K | 30K | 86K | 137K | 0 |
| Total Assets | 12K | 36K | 88K | 146K | 12K |
| Total Liabilities | 82K | 47K | 93K | 2M | 1M |
| Shareholder Equity | -70K | -11K | -5K | -2M | -1M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -8K | -30K | -86K | -137K | 0 |
Cash flow positioning
Latest Full Year
Operating Cash Flow
46K
-12.4% YoY
Capital Expenditures
0
Free Cash Flow
46K
-12.4% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-29.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.